Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 5/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 4/20 | 0.35 |
| ▸ | TP53 | P04637 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6237322 | 0.81 | L3MBTL1 (0.40) | ALDH1A1HPGDAOC3SMN1; SMN2L3MBTL1 | |
| SCHEMBL2093652 | 0.81 | EPHX2 (0.49) | LMNATAAR1HRH3ALDH1A1RAB9A | |
| SCHEMBL1822061 | 0.79 | HTR2A (0.41) | HRH3AOC3 | |
| SCHEMBL499957 | 0.76 | AOC3 (0.47) | TAAR1ALDH1A1AOC3MEN1KMT2A | |
| SCHEMBL1411957 | 0.74 | CFTR (0.44) | LMNATAAR1ALDH1A1HPGDAOC3 | |
| SCHEMBL1091848 | 0.68 | KMT2A (0.48) | LMNATAAR1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL696711 | 0.67 | CALM1 (0.46) | LMNACALM1TAAR1HRH3ALDH1A1 | |
| SCHEMBL27968331 | 0.66 | CALM1 (0.58) | LMNACALM1ALDH1A1HPGDRAB9A | |
| SCHEMBL8195591 | 0.66 | CALM1 (0.57) | LMNACALM1TAAR1HRH3ALDH1A1 | |
| SCHEMBL9389496 | 0.65 | SLC6A3 (0.49) | LMNACALM1TDP1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1751095-B1 | SUBSTITUTED CYCLOHEXYLCARBOXYLIC ACID DERIVATIVES | GRUENENTHAL GMBH (DE) | 2014-06-18 | — | — | EP | claimed |
| JP-4688381-B2 | — | — | 2011-05-25 | — | — | JP | claimed |
| WO-2010135427-A2 | TRIOXANE MONOMERS AND DIMERS | THE JOHNS HOPKINS UNIVERSITY (US) | 2010-11-25 | — | — | WO | claimed |
| US-7241802-B2 | Substituted cyclohexylcarboxylic acid amide compounds | GRUENENTHAL GMBH (DE) | 2007-07-10 | — | — | US | claimed |
| US-20070105941-A1 | Substituted cyclohexylcarboxylic acid amide compounds | GRUENENTHAL GMBH (DE) | 2007-05-10 | — | — | US | claimed |
| EP-1192133-B1 | N-CYCLOPENTYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO INC (US) | 2006-11-02 | — | — | EP | claimed |
| US-6538002-B1 | In particular, these compounds are useful as modulators of the chemokine receptors CCR-5 and/or CCR-3. as antiinflammatory agents | MERCK & CO., INC. | 2003-03-25 | — | — | US | claimed |
| US-20020120146-A1 | N-cyclopentyl modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2002-08-29 | — | — | US | claimed |
| US-6432981-B1 | BLOCKS HUMAN IMMUNODEFICIENCY VIRUS (HIV) FROM ENTERING CELLS; AUTOIMMUNE DISEASES; ANTIALLERGENS, ANTIINFLAMMATORY AND ANTIASTHMATIC AGENTS | MERCK & CO., INC. | 2002-08-13 | — | — | US | claimed |
| EP-1192133-A1 | N-CYCLOPENTYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Merck & Co., Inc. (US) | 2002-04-03 | — | — | EP | claimed |
| US-6358979-B1 | FOR THERAPY AND PROPHYLAXIS OF ASTHMA, ALLERGIC RHINITIS, DERMATITIS, CONJUNCTIVITIS, ATHEROSCLEROSIS OR RHEUMATOID ARTHRITIS, INFECTION BY HIV, TREATING INFECTION BY HIV, DELAYING OF THE ONSET OF AIDS | MERCK & CO., INC. | 2002-03-19 | — | — | US | claimed |
| WO-2000076511-A1 | CYCLOPENTYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2000-12-21 | — | — | WO | claimed |
| WO-2000076514-A1 | CYCLOPENTYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2000-12-21 | — | — | WO | claimed |
| WO-2000076972-A1 | N-CYCLOPENTYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2000-12-21 | — | — | WO | claimed |
| WO-2022035763-A1 | BORON CONTAINING COMPOUNDS AND THEIR USES | 5METIS, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
| WO-2021061823-A1 | CHEMICAL COMPOUNDS | Boragen, Inc. (US) | 2021-04-01 | — | — | WO | disclosed |
| WO-2020264581-A1 | BORON CONTAINING COMPOUNDS AND THEIR USES | Boragen, Inc. (US) | 2020-12-30 | — | — | WO | disclosed |
| EP-0478974-B1 | N-Heteroaryl-2-nitroanilines | BASF AG (DE) | 1995-12-27 | — | — | EP | disclosed |
| US-5298515-A | N-hetaryl-2-nitroanilines | BASF AKTIENGESELLSCHAFT (DE) | 1994-03-29 | — | — | US | disclosed |
| EP-0478974-A1 | N-Heteroaryl-2-nitroanilines | BASF Aktiengesellschaft (DE) | 1992-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105941-A1 | Substituted cyclohexylcarboxylic acid amide compounds | OPRL1, OPRK1, HCAR1 | LMNA 2573/4885CALM1 406/4885TAAR1 58/4885 |
| US-20020120146-A1 | N-cyclopentyl modulators of chemokine receptor activity | CCR1, CCR3, CCR5 | LMNA 4563/4885CALM1 4008/4885TAAR1 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.